Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Vali A. Papadimitrakopoulou, MD, and Fabrice Denis, MD, PhD, on Lung Cancer: Improving Survival With an App

Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discuss findings from a phase III trial on an app used between visits for early detection of symptomatic relapse and complications in high-risk lung cancer patients (Abstract LBA9006). To see Dr. Denis discuss this study in French, click here.

To see the French language version of this discussion, click here.

Issues in Oncology

Eric Roeland, MD, and Timothy E. Quill, MD, on the Debate Over Physician-Assisted Death

Eric Roeland, MD, of the University of California, San Diego, and Timothy E. Quill, MD, of the University of Rochester Medical Center, discuss the debate on whether physician-assisted death should be a legally available option at the end of life when neither palliative nor hospice care is satisfactory.

Multiple Myeloma

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial

Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). To see the Italian version of this interview, please click here.

Breast Cancer

Paul E. Goss, MD, PhD, on Postmenopausal Early-Stage Breast Cancer: Extending Letrozole Treatment

Paul E. Goss, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, discusses disease-free survival results from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA1).

Neuroendocrine Tumors

Heinz-Josef Lenz, MD, and Jonathan R. Strosberg, MD, on the NETTER-1 Trial for Midgut Neuroendocrine Tumors

Heinz-Josef Lenz, MD, of the University of Southern California, and Jonathan R. Strosberg, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discuss efficacy and safety results in patients with midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 4005).

Mar

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Vali A. Papadimitrakopoulou, MD, and Fabrice Denis, MD, PhD, on Lung Cancer: Improving Survival With an App

Eric Roeland, MD, and Timothy E. Quill, MD, on the Debate Over Physician-Assisted Death

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial

Paul E. Goss, MD, PhD, on Postmenopausal Early-Stage Breast Cancer: Extending Letrozole Treatment

Heinz-Josef Lenz, MD, and Jonathan R. Strosberg, MD, on the NETTER-1 Trial for Midgut Neuroendocrine Tumors

Dynamic Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis

Pembrolizumab With or Without Lenvatinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

AI Model for Predicting Oncotype DX 21-Gene Recurrence Score

Breast Cancer Recurrence Remains Low Even After 10 Years With Radiotherapy Tailored to Patient’s Individual Risk